ABCL FY 2025 Earnings — AbCellera Biologics Inc. Revenue & Financial Results | Market Cap Arena

ABCLAbCellera Biologics Inc.

$1B

FY 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$75M+160.6% YoY

Gross Profit

$75M100.0% margin

Operating Income

-$217M-289.0% margin

Net Income

-$146M-194.9% margin

EPS (Diluted)

$-0.49

Cash Flow

Operating Cash Flow

-$131M

Free Cash Flow

-$174M

Stock-Based Comp.

$56M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$216M

Stockholders' Equity

$1.1B

Cash & Equivalents

$155M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$75M	$29M	+160.6%
Gross Profit	$75M	$29M	+160.6%
Operating Income	-$217M	-$315M	+31.0%
Net Income	-$146M	-$163M	+10.1%